In an August 2025 update from Unlimit Health, the organization said schistosomiasis remained highly endemic in Niger, with 69 of 72 health districts considered at risk. It said WHO-donated praziquantel was already in-country but due to expire in October 2025, compressing the delivery window and raising the stakes for the national campaign.
Why Niger schistosomiasis treatment could not wait
WHO says schistosomiasis is an acute and chronic parasitic disease spread through contact with infested freshwater and that school-aged children are especially vulnerable because of routine water exposure. The agency estimates 253.7 million people required preventive treatment in 2024, and nearly 94% of those needing treatment lived in Africa.
That matters in Niger because the disease does not just cause illness in the abstract. Untreated infections can sap children’s energy, damage learning and keep health systems stuck in repeated cycles of treatment instead of steady progress toward elimination. When a campaign window closes in a high-risk setting, the effects can linger far beyond one missed distribution round.
How emergency funding kept Niger schistosomiasis treatment on track
The financing gap opened after USAID funding was withdrawn in early 2025, according to a later Unlimit Health funders note, which said £135,200 in emergency support from The Life You Can Save allowed the Ministry of Health to keep the campaign moving. Unlimit Health has described the outcome as treatment for more than 1.2 million school-aged children, preserving continuity of care just as the country’s 2025 window for delivery was closing.
The July 2025 drive was carried out through schools and door-to-door distribution, a combined approach that matters in a country where school enrollment gaps have long made school-only delivery less reliable. The rescue was not merely about spending emergency money quickly; it was about matching financing to the operational reality on the ground before medicines expired and trained local networks stood idle.
Years of progress, and a warning for the next funding gap
The wider lesson is not confined to one country. WHO’s 2025 global report on neglected tropical diseases says programs are being severely disrupted by reduced funding, with official development assistance for NTDs down 41% between 2018 and 2023. That makes emergency stopgaps valuable, but it also underscores how fragile elimination strategies become when donor funding disappears faster than national systems can replace it.
That fragility has deep roots. A 2011 PLOS Neglected Tropical Diseases study found that Niger’s national program delivered 4.3 million schistosomiasis and soil-transmitted helminth treatments in its first two years, and it showed why community distribution mattered in a country where school enrollment was too low for school-based delivery alone.
Even with that progress, a 2019 multicountry analysis summarized by RTI reported that Niger was the only program in a nine-country review that had not reached the disease-control target within two treatment rounds, a sign that the last stretch of control can be harder and more expensive than early gains suggest.
The funding picture also grew more unstable after the 2023 coup. Reuters reported in July 2023 that the European Union and France had suspended financial support and the United States said its assistance to Niger was in jeopardy, illustrating how quickly political shocks can ripple into health programs.
For now, the emergency bridge held. But the episode is also a warning: donated medicine, trained local distributors and years of disease-control gains mean little if financing collapses just before delivery. The next phase of Niger’s campaign will depend less on last-minute rescues than on steadier funding and stronger domestic planning.
